MAPT and Alzheimer disease: Some studies have demonstrated that [18F]flortaucipir, [18F]MK-6240, and [18F]RO948 tau PET correlate with cognitive decline in participants with AD and/or cognitively normal controls (particularly those with positive β-amyloid [Aβ] biomarkers) [10–17].